Novo Nordisk (NOV)Novo Nordisk A/S Class BXETR_DLY:NOVmgiulianiNovo Nordisk (NVO) reported strong first-quarter earnings on May 6, 2026, with sales jumping 32% to reach 96.8 billion Danish kroner (~$15.2 billion). Driven by soaring demand for its popular GLP-1 weight-loss and diabetes drugs like Wegovy and Ozempic, the company beat earnings estimates and raised its full-year 2026 guidance. Earnings Per Share (EPS): Novo reported a diluted Q1 EPS of $1.04, beating the average analyst estimates of $0.87. The company raised its full-year guidance, projecting adjusted sales and operating profit growth of between -4% and -12% at constant exchange rates. The company's next earnings report, covering the second quarter, is scheduled for release on August 5, 2026.